Elastagen Pty Ltd is a clinical-stage medical-device company that is pioneering Elastatherapy™, which uses the human protein elastin to naturally repair and augment the skin. The company has arisen out of patented research conducted by Prof. Tony Weiss’s group and the first clinical trials have demonstrated the biocompatability and safety of their synthetic human elastin in human subjects. Prof. Weiss’s work on elastin for burns treatment was highlighted in the 2010 AMMRF Profile. Elastagen is a venture-backed private company based in Sydney. Investors include ATP Innovations, Brandon Capital and GBS Ventures.
AMMRF Technical Voucher Fund receives funding from MTPConnect’s Project Fund Program Recognised as a big, bold idea to improve the productivity, competitiveness and innovative capacity of Australia’s medtech, biotech and pharmaceutical
Hazer Group was established in 2010 from technology developed at UWA to produce clean hydrogen and high-grade synthetic graphite from natural gas and iron ore. Its development depended on AMMRF microscopy @ UWA. They have announced the successful
Prof. Tony Weiss from the University of Sydney in conjunction with Elastagen Pty Ltd has been awarded a $1million Translation Award from the Wellcome Trust to fast track their elastin-based synthetic skin to clinical trials. They will refine and